{
  "id": "672ecd70-7a9f-4bdc-9d19-1bf04a5e3fbb",
  "title": "Gilead reports positive long-term data for Yescarta for NHL",
  "link": "https://seekingalpha.com/news/4380291-gilead-reports-positive-long-term-data-for-yescarta-for-nhl?utm_source=feed_news_all\u0026utm_medium=referral\u0026feed_item_type=news",
  "description": "",
  "author": "",
  "published": "Mon, 09 Dec 2024 19:02:18 -0500",
  "source": "https://seekingalpha.com/market_currents.xml",
  "categories": [
    "gild"
  ],
  "byline": "Val Brickates Kennedy",
  "length": 385,
  "excerpt": "Gilead’s (GILD) Kite unit reported positive results from a five-year follow-up of a Phase 2 study for its cell therapy Yescarta in certain patients with non-Hodgkin lymphoma.",
  "siteName": "Seeking Alpha",
  "favicon": "https://seekingalpha.com/samw/static/images/favicon-192x192.png",
  "text": "Healthcare Sundry Photography Gilead’s (NASDAQ:GILD) Kite unit reported positive results from a five-year follow-up of a Phase 2 study for its cell therapy Yescarta in certain patients with non-Hodgkin lymphoma, or NHL. The analysis showed that after a median follow-up of more thanRecommended For YouAbout GILD StockCompare to PeersRelated StocksGILD-Trending AnalysisTrending News",
  "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1189813806/image_1189813806.jpg?io=getty-c-w750",
  "html": "\u003cdiv id=\"readability-page-1\" class=\"page\"\u003e\u003cdiv id=\"content\"\u003e\u003carticle data-test-id=\"grid-container\"\u003e\u003cdiv\u003e\u003cdiv data-test-id=\"grid-col-main\"\u003e\u003cdiv data-test-id=\"card-container\"\u003e\u003cheader\u003e\u003cdiv data-test-id=\"quick-links\"\u003e\u003cul\u003e\u003cli\u003e\u003ca data-test-id=\"theme-links-item\" href=\"https://seekingalpha.com/market-news/healthcare#source=section%3Amain_content%7Csection_asset%3Athemes%7Cbutton%3Ahealthcare%7Cfirst_level_url%3Anews\"\u003e\u003cspan\u003e\u003cspan\u003eHealthcare\u003c/span\u003e\u003c/span\u003e\u003c/a\u003e\u003c/li\u003e\u003c/ul\u003e\u003c/div\u003e\u003c/header\u003e\u003cdiv\u003e\u003cdiv data-test-id=\"content-container\"\u003e\u003cfigure data-type=\"getty-image\"\u003e \u003cpicture\u003e \u003cimg src=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1189813806/image_1189813806.jpg?io=getty-c-w750\" alt=\"Gilead Sciences, Inc. headquarters in Silicon Valley\" data-id=\"1189813806\" data-type=\"getty-image\" width=\"1536px\" height=\"1025px\" srcset=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1189813806/image_1189813806.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1189813806/image_1189813806.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1189813806/image_1189813806.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1189813806/image_1189813806.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1189813806/image_1189813806.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1189813806/image_1189813806.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1189813806/image_1189813806.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1189813806/image_1189813806.jpg?io=getty-c-w240 240w\" sizes=\"(max-width: 768px) calc(100vw - 36px), (max-width: 1024px) calc(100vw - 132px), (max-width: 1200px) calc(66.6vw - 72px), 600px\"/\u003e \u003c/picture\u003e \u003cfigcaption data-type=\"getty-image\"\u003e\u003cp\u003eSundry Photography\u003c/p\u003e\u003c/figcaption\u003e \u003c/figure\u003e\u003cp\u003eGilead’s (\u003cspan\u003eNASDAQ:\u003ca href=\"https://seekingalpha.com/symbol/GILD\" title=\"Gilead Sciences, Inc.\"\u003eGILD\u003c/a\u003e\u003c/span\u003e) Kite unit reported positive results from a five-year follow-up of a Phase 2 study for its cell therapy Yescarta in certain patients with non-Hodgkin lymphoma, or NHL.\u003c/p\u003e \u003cp\u003eThe analysis showed that after a median follow-up of more than\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv data-test-id=\"recommended-section\"\u003e\u003cdiv\u003e\u003cp\u003e\u003ch4 data-test-id=\"recommended-for-you-card-title\"\u003eRecommended For You\u003c/h4\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv data-test-id=\"post-skeleton\"\u003e\u003c/div\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv data-test-id=\"right-rail\"\u003e\u003cdiv data-test-id=\"about-symbol-card\"\u003e\u003cdiv\u003e\u003cp\u003e\u003ch3 data-test-id=\"about-symbol-card-title\"\u003eAbout GILD Stock\u003c/h3\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv\u003e\u003cdiv data-test-id=\"about-symbol-chart\"\u003e\u003ctable data-test-id=\"table\"\u003e\u003cthead data-test-id=\"table-header\"\u003e\u003c/thead\u003e\u003ctbody data-test-id=\"table-body\"\u003e\u003c/tbody\u003e\u003c/table\u003e\u003cul\u003e\u003cli\u003e\u003c/li\u003e\u003cli\u003e\u003c/li\u003e\u003cli\u003e\u003c/li\u003e\u003cli\u003e\u003c/li\u003e\u003cli\u003e\u003c/li\u003e\u003cli\u003e\u003c/li\u003e\u003cli\u003e\u003c/li\u003e\u003cli\u003e\u003c/li\u003e\u003c/ul\u003e\u003c/div\u003e\u003cp\u003e\u003ca data-test-id=\"about-symbol-footer-link\" href=\"https://seekingalpha.com/comparison/new/MCUyQ2dpbGQ=#source=first_level_url%3Anews%7Csection%3Aabout%7Cbutton%3Acompare\" target=\"_blank\"\u003e\u003cspan\u003eCompare to Peers\u003c/span\u003e\u003c/a\u003e\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv data-test-id=\"suggested-symbols-card\"\u003e\u003cdiv\u003e\u003cp\u003e\u003ch3 data-test-id=\"suggested-symbols-card-title\"\u003eRelated Stocks\u003c/h3\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv\u003e\u003ctable data-test-id=\"table\"\u003e\u003cthead data-test-id=\"table-header\"\u003e\u003c/thead\u003e\u003ctbody data-test-id=\"table-body\"\u003e\u003ctr\u003e\u003ctd\u003e\u003ca data-test-id=\"gild-link\" href=\"https://seekingalpha.com/symbol/GILD#source=first_level_url%3Anews%7Csection%3Aright_rail%7Csection_asset%3Arelated_stocks%7Csymbol%3Agild%7Cline%3A1\"\u003eGILD\u003c/a\u003e\u003c/td\u003e\u003ctd\u003e-\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/table\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv data-test-id=\"trending-articles-cards-container\"\u003e\u003cdiv\u003e\u003cp\u003e\u003ch2 data-test-id=\"trending-articles-cards-title\" id=\"trending-articles-cards-container\"\u003eTrending Analysis\u003c/h2\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv data-test-id=\"post-skeleton\"\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv data-test-id=\"trending-news-cards-container\"\u003e\u003cdiv\u003e\u003cp\u003e\u003ch2 data-test-id=\"trending-news-cards-title\" id=\"trending-news-cards-container\"\u003eTrending News\u003c/h2\u003e\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003c/div\u003e\u003c/div\u003e\u003c/article\u003e\u003c/div\u003e\u003c/div\u003e",
  "readingTime": "Less than 1 min",
  "publishedTime": "2024-12-10T00:02:18Z",
  "modifiedTime": "2024-12-09T19:02:36-05:00"
}
